Theratechnologies Receives FDA Approval for EGRIFTA WR(TM) (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Stock Information for Theratechnologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Theratechnologies Inc.

Theratechnologies Provides Update on Sale Process
Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.